[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Messina\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":40},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100599145","phase-4-short-term-dual-antiplatelet-therapy-with-early-transi-tion-to-low-dose-antiplatelet-monotherapy-using-ti-cagrelor-in-chronic-coronary-artery-disease-100599145",false,"NCT07080684","Short-Term Dual Antiplatelet Therapy With Early Transi-tion to Low-dose Antiplatelet Monotherapy Using Ti-cagRelor in Chronic Coronary Artery Disease","Short-Term Dual Antiplatelet Therapy With Early Transition to Low-dose Antiplatelet Monotherapy Using ticagRelor in Chronic Coronary Artery Disease","STELAR","Inclusion Criteria:\n\n* Age ≥18 years at the time of informed consent.\n* Diagnosis of chronic coronary syndrome (CCS) according to ESC guidelines.\n* Undergoing successful PCI with implantation of one or more new-generation drug-eluting stents (DES).\n* Indication for dual antiplatelet therapy (DAPT) following PCI.\n* Willingness and ability to comply with all study procedures and follow-up assessments.\n* Signed informed consent prior to any study-specific procedure.\n* Creatinine clearance ≥30 mL\u002Fmin, calculated using the Cockcroft-Gault formula.\n* Life expectancy greater than 1 year in the investigator's judg-ment.\n* Hemodynamically stable at the time of randomization.\n* Acceptable bleeding risk profile: patients fulfilling ARC-HBR criteria may be included only if the treating physician deems a 6-month antiplatelet regimen to be safe.\n* No contraindications to study drugs, including aspirin, clopi-dogrel, or ticagrelor.\n\nExclusion Criteria:\n\n* Presentation with acute coronary syndrome (ACS), including STEMI, NSTEMI, or unstable angina within the previous 6 mon-ths.\n* Planned staged PCI or revascularization procedure within 6 months after index PCI.\n* Requirement for long-term oral anticoagulation therapy, such as for atrial fibrillation, mechanical heart valves, or venous thromboembolism.\n* History of major bleeding, including gastrointestinal or intra-cranial bleeding, within the past 6 months.\n* Severe hepatic impairment, active liver disease, or transamina-ses \\>3× upper limit of normal.\n* Known platelet disorder, coagulopathy, or thrombocytopenia (\\\u003C100,000\u002Fmm³).\n* Contraindication or hypersensitivity to aspirin, clopidogrel, or ticagrelor, or known drug interaction that precludes their use.\n* Ongoing active bleeding or high risk of bleeding that, in the opinion of the investigator, precludes DAPT.\n* Pregnancy or breastfeeding, or women of childbearing potential who are not using effective contraception.\n* Life expectancy \\\u003C1 year due to non-cardiovascular comorbidi-ties (e.g., cancer, advanced renal failure).\n* Participation in another interventional clinical trial that may interfere with the outcomes of this study.\n* Severe anemia (hemoglobin \\\u003C9 g\u002FdL) not corrected before ran-domization.\n* Inability or unwillingness to provide informed consent or ad-here to study follow-up.\n* Prior stroke with residual neurological deficit or history of di-sabling stroke (mRS ≥3).","ALL","18 Years",{"count":20,"type":21},1000,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","This is a prospective, multicenter, randomized, open-label trial with blinded endpoint adjudication (PROBE design), comparing one-month dual antiplatelet therapy (DAPT) with low-dose ticagrelor (60 mg BID) followed by ticagrelor monotherapy to standard 6-month DAPT with aspirin and clopidogrel in patients with chronic coronary syndrome (CCS) undergoing percutaneous coronary intervention (PCI). The primary endpoint is a composite of cardiovascular death, all-cause death, myocardial infarction, disabling stroke, target lesion revascularization (TLR), and major bleeding. The study aims to evaluate whether the short DAPT strategy reduces ischemic events while maintaining bleeding safety.",[27],"Chronic Coronary Syndrome","NOT_YET_RECRUITING","2025-07-14",{"date":31,"type":32},"2025-07-23","ACTUAL",{"date":34,"type":21},"2025-12-01",{"date":36,"type":21},"2027-09",{"name":38,"class":39},"University of Messina","OTHER",""]